Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-11: Inclisiran in ASCVD or ASCVD Risk-Equivalents
NCT03400800Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Nov 2017
- Primary completion
- Jul 2019
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 7
01
Overview
A Phase 3 trial of inclisiran in hypercholesterolemia, sponsored by The Medicines Company. Started Nov 2017; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03400800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400800.